Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248501432> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4248501432 endingPage "4724" @default.
- W4248501432 startingPage "4724" @default.
- W4248501432 abstract "4724 Background: Pts with International Germ Cell Cancer Collaborative Group (IGCCCG) “poor prognosis” disease achieve only a 41% 5-year progression-free survival (PFS) with standard chemotherapy. Pts who do not achieve a complete remission with BEP chemotherapy or who relapse after such treatment have a still worse prognosis. The clinical impact of HDC in such pts is still unclear. Methods: Pts with germ cell cancer with IGCCCCG “poor prognosis” disease at diagnosis (or, earlier, with Indiana group C) or with recurrent or refractory (i.e., less than marker negative partial remission) disease after initial BEP chemotherapy were eligible for HDC. Results: Between June 1996 and April 2003, 18 pts underwent one (13 pts) or two (5 pts) cycles of HDC with ICE (ifosfamide 10g/m2, carboplatin 1,500mg/m2 and etoposide 2,400mg/m2); 17 pts), or etoposide (1500mg/m2) plus thiotepa (900 mg/m2); 1 pt), in 6 pts as consolidation after BEP and in 12 pts for recurrent disease (7 pts) or refractoriness to BEP (5 pts). In the consolidation group (6 pts), with a median follow-up of 42 months (range 10–72 months), there are no events. Thus the PFS and overall survival (OS) at 3.5 years is 100%. In contrast, with a median follow-up of 18 months, the median PFS and OS for pts with recurrent or refractory disease subgroup are 4 months (0–40+) and 18 months (4–40+), respectively. In this subgroup, 10 pts relapsed by 8 months post-HDC and only 2 are progression-free at 20 and 40 months. Conclusions: Despite the small number of pts and short follow-up, these results compare at least as favorably to the outcome obtained with standard chemotherapy in pts with “poor prognosis” at diagnosis. In contrast the outcome of pts with recurrent or refractory disease after initial BEP chemotherapy are not better than those obtained with standard salvage chemotherapy. No significant financial relationships to disclose." @default.
- W4248501432 created "2022-05-12" @default.
- W4248501432 creator A5016970264 @default.
- W4248501432 creator A5023395241 @default.
- W4248501432 creator A5023641663 @default.
- W4248501432 creator A5025671115 @default.
- W4248501432 creator A5036944303 @default.
- W4248501432 creator A5050764323 @default.
- W4248501432 creator A5062646243 @default.
- W4248501432 creator A5065268415 @default.
- W4248501432 date "2004-07-15" @default.
- W4248501432 modified "2023-09-24" @default.
- W4248501432 title "Clinical outcome of germ cell cancer patients (pts) treated with high-dose chemotherapy with stem cell support (HDC) –a single center experience" @default.
- W4248501432 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.4724" @default.
- W4248501432 hasPublicationYear "2004" @default.
- W4248501432 type Work @default.
- W4248501432 citedByCount "0" @default.
- W4248501432 crossrefType "journal-article" @default.
- W4248501432 hasAuthorship W4248501432A5016970264 @default.
- W4248501432 hasAuthorship W4248501432A5023395241 @default.
- W4248501432 hasAuthorship W4248501432A5023641663 @default.
- W4248501432 hasAuthorship W4248501432A5025671115 @default.
- W4248501432 hasAuthorship W4248501432A5036944303 @default.
- W4248501432 hasAuthorship W4248501432A5050764323 @default.
- W4248501432 hasAuthorship W4248501432A5062646243 @default.
- W4248501432 hasAuthorship W4248501432A5065268415 @default.
- W4248501432 hasConcept C104317684 @default.
- W4248501432 hasConcept C121608353 @default.
- W4248501432 hasConcept C126322002 @default.
- W4248501432 hasConcept C143998085 @default.
- W4248501432 hasConcept C185592680 @default.
- W4248501432 hasConcept C2776694085 @default.
- W4248501432 hasConcept C2776938808 @default.
- W4248501432 hasConcept C2779122487 @default.
- W4248501432 hasConcept C28328180 @default.
- W4248501432 hasConcept C54355233 @default.
- W4248501432 hasConcept C55493867 @default.
- W4248501432 hasConcept C71924100 @default.
- W4248501432 hasConcept C86803240 @default.
- W4248501432 hasConceptScore W4248501432C104317684 @default.
- W4248501432 hasConceptScore W4248501432C121608353 @default.
- W4248501432 hasConceptScore W4248501432C126322002 @default.
- W4248501432 hasConceptScore W4248501432C143998085 @default.
- W4248501432 hasConceptScore W4248501432C185592680 @default.
- W4248501432 hasConceptScore W4248501432C2776694085 @default.
- W4248501432 hasConceptScore W4248501432C2776938808 @default.
- W4248501432 hasConceptScore W4248501432C2779122487 @default.
- W4248501432 hasConceptScore W4248501432C28328180 @default.
- W4248501432 hasConceptScore W4248501432C54355233 @default.
- W4248501432 hasConceptScore W4248501432C55493867 @default.
- W4248501432 hasConceptScore W4248501432C71924100 @default.
- W4248501432 hasConceptScore W4248501432C86803240 @default.
- W4248501432 hasIssue "14_suppl" @default.
- W4248501432 hasLocation W42485014321 @default.
- W4248501432 hasOpenAccess W4248501432 @default.
- W4248501432 hasPrimaryLocation W42485014321 @default.
- W4248501432 hasRelatedWork W1785812351 @default.
- W4248501432 hasRelatedWork W2035589037 @default.
- W4248501432 hasRelatedWork W2147316169 @default.
- W4248501432 hasRelatedWork W2149296823 @default.
- W4248501432 hasRelatedWork W2341246941 @default.
- W4248501432 hasRelatedWork W2600735778 @default.
- W4248501432 hasRelatedWork W2789166760 @default.
- W4248501432 hasRelatedWork W30231677 @default.
- W4248501432 hasRelatedWork W6933653 @default.
- W4248501432 hasRelatedWork W2133000900 @default.
- W4248501432 hasVolume "22" @default.
- W4248501432 isParatext "false" @default.
- W4248501432 isRetracted "false" @default.
- W4248501432 workType "article" @default.